secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2021-09-13T23:59:59+00:00
Accession:  0001564590-21-047679
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma Announces Positive Phase 1b/2a Results for ATYR1923 in Pulmonary Sarcoidosis
--------------------------------------------------------------------------------

- ATYR1923 safe and well-tolerated with no drug-related serious adverse events in 37-patient pulmonary sarcoidosis trial.
- 5.0 mg/kg group achieved 58% steroid reduction from baseline and 33% of patients tapered completely off steroids.
- Absolute improvement in forced vital capacity (FVC) of 3.3% at week 24 in 5.0 mg/kg group vs placebo.
- Clinically meaningful improvements in dyspnea, cough, fatigue and King's Sarcoidosis scores in 5.0 mg/kg group.
- Company plans FDA end-of-Phase 2 meeting and expects to initiate registrational trial in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000156459021047679/0001564590-21-047679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000156459021047679/life-8k_20210913.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-047679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer